Science & Enterprise subscription

Please share Science & Enterprise

RSS
Follow by Email
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn

Donate to our blog

Your support will help Science & Enterprise continue to provide science news for business people and business news for scientists.

Grid Computing Harnessed for Childhood Cancer Research

An international consortium is seeking crowdsourced computing power to screen drug candidates for treating a number of cancers affecting children. . . . → Read More: Grid Computing Harnessed for Childhood Cancer Research

Biotech, Pharma Partner on Neuro Drug Discovery

A collaboration between a biotechnology enterprise tracking defective proteins and pharmaceutical company plans to discover new treatments for neurodegenerative disorders. . . . → Read More: Biotech, Pharma Partner on Neuro Drug Discovery

Stem Cell Therapy Company Formed, Staked to $225M

A pharmaceutical company and health care venture investor are forming BlueRock Therapeutics, a biotechnology enterprise to design regenerative medicine treatments with stem cells. . . . → Read More: Stem Cell Therapy Company Formed, Staked to $225M

Ostrich Antibodies to Fight Resistant Infections

A biotechnology company developing antibodies grown in ostrich eggs is partnering with a Boston hospital to test a new treatment for Clostridium difficile, or C. difficile, a stubborn infection, increasingly resistant to antibiotics, and often contracted in hospitals. . . . → Read More: Ostrich Antibodies to Fight Resistant Infections

Takeda Awarded $19.8 Million for Zika Vaccine

Takeda Pharmaceutical Company is receiving $19.8 million from a U.S. public health agency for initial steps to develop a vaccine to prevent Zika infections. . . . → Read More: Takeda Awarded $19.8 Million for Zika Vaccine

Spacecraft Returns with Space Station Research Samples

A SpaceX Dragon spacecraft returned today with samples from several biomedical research studies conducted by astronauts on the International Space Station. . . . → Read More: Spacecraft Returns with Space Station Research Samples

Hemophilia Therapy Candidate Given Breakthrough Status

(Public Domain Pictures/Pixabay)

4 September 2015. A synthetic antibody designed to prevent bleeding episodes among people with the most common type of hemophilia received a breakthrough therapy designation from the U.S. Food and Drug Administration. The pharmaceutical company Roche says FDA assigned the designation its biologic therapy code-named ACE910, now being tested in clinical . . . → Read More: Hemophilia Therapy Candidate Given Breakthrough Status

Spin-Off Biotech Formed for Autoimmune Disorders

(Centers for Disease Control and Prevention)

2 June 2015. Drug maker Astellas Pharma Inc. in Tokyo and Anokion SA, a biotechnology company in Lausanne, Switzerland, are forming Kanyos Bio Inc., a spin-off enterprise to develop therapy candidates for autoimmune diseases. The deal could bring Kanyos Bio, based in Cambridge, Massachusetts, as much as $760 . . . → Read More: Spin-Off Biotech Formed for Autoimmune Disorders

Astellas Getting First Access to Leukemia Antibody

Acute myeloid leukemia cells (Cancer Genome Atlas)

3 April 2015. MD Anderson Cancer Center in Houston is granting Astellas Pharma Inc. in Tokyo an option to license MD Anderson’s discovery of a synthetic antibody showing promise as a treatment for acute myeloid leukemia. For the licensing option, MD Anderson could earn up to $26 . . . → Read More: Astellas Getting First Access to Leukemia Antibody

XPrize Awards $5.25M for Lunar Technologies

(NASA.gov)

26 January 2015. A competition to develop new technologies for landing and robotic exploration of the moon awarded $5.25 million in 9 prizes to 5 private companies, as part of the Google Lunar XPrize challenge. The companies — from the U.S., Germany, Japan, and India — received the prizes for their design and . . . → Read More: XPrize Awards $5.25M for Lunar Technologies